Rajinder Kumar - Titan Pharmaceuticals Director
| TTNP Stock | USD 7.01 0.31 4.23% |
Director
Dr. Rajinder Kumar serves as Director of the Company. He has served as the Chairman and Chief Executive Officer of MeRaD Pharmaceutical Ltd. in Cambridge U.K. since May 2009. He has also served as President and Chief Medical Officer of Vitas Pharma in Hyderabad, India since he founded such company in 2010. For the decade prior to joining MeRaD, he served in various executive capacities with Dr. Reddys Labs, Ranbaxy Laboratories Limited, Synaptic Pharmaceutical LLP and Glaxo SmithKline Beecham since 2017.
| Age | 61 |
| Tenure | 7 years |
| Phone | 650 244 4990 |
| Web | https://www.titanpharm.com |
Titan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.749) % which means that it has lost $0.749 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3914) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dean Kollintzas | GeoVax Labs | 43 | |
| Justin Yorke | Processa Pharmaceuticals | 50 | |
| MD FACOG | GeoVax Labs | 61 | |
| Winson Ho | Lixte Biotechnology Holdings | N/A | |
| Harriet Robinson | GeoVax Labs | 86 | |
| Roger Tung | Salarius Pharmaceuticals | 58 | |
| Jeffrey Capello | Salarius Pharmaceuticals | 53 | |
| Philip Palmedo | Lixte Biotechnology Holdings | 80 | |
| Kathleen Mullinix | Lixte Biotechnology Holdings | 69 | |
| Michelle Stacy | Salarius Pharmaceuticals | 62 | |
| John Sculley | Salarius Pharmaceuticals | 76 | |
| Stuart Randle | Salarius Pharmaceuticals | 58 | |
| Virgil Thompson | Processa Pharmaceuticals | 77 | |
| Yun Yen | Lixte Biotechnology Holdings | N/A | |
| Stephen Forman | Lixte Biotechnology Holdings | N/A | |
| Susan Berland | Senti Biosciences | 69 | |
| Peter Hutt | Salarius Pharmaceuticals | 83 | |
| Patrick Lin | Processa Pharmaceuticals | 59 | |
| John Spencer | GeoVax Labs | 76 | |
| Marc Kozin | Salarius Pharmaceuticals | 56 | |
| Randal Chase | GeoVax Labs | 67 | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.75 |
Titan Pharmaceuticals Leadership Team
Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Rubin, Executive Chairman of the Board | ||
| Rajinder Kumar, Director | ||
| Brian Crowley, Senior Administration | ||
| Sunil Bhonsle, President, Secretary and Director | ||
| James McNab, Director | ||
| Federico Recli, Director | ||
| David MacFarlane, Independent Director | ||
| Joseph Akers, Director | ||
| Eurelio Cavalier, Independent Director | ||
| Marc MD, Ex Director | ||
| David Lazar, Principal Officer | ||
| Scott Smith, Director | ||
| Joe Schrei, Executive Operations | ||
| Katherine BeebeDeVarney, COO President | ||
| Ley Smith, Independent Director | ||
| Dane Hallberg, Executive Vice President and Chief Commercial Officer | ||
| Jennifer Kiernan, Executive Coordinator | ||
| Victor Bauer, Independent Director | ||
| Seghi Recli, Lead Director | ||
| Mike Fritz, National Director |
Titan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (39.55) % | ||||
| Current Valuation | 497.74 K | ||||
| Shares Outstanding | 914.23 K | ||||
| Shares Owned By Insiders | 45.46 % | ||||
| Shares Owned By Institutions | 5.51 % | ||||
| Number Of Shares Shorted | 3.91 K | ||||
| Price To Earning | (3.60) X | ||||
| Price To Book | 1.00 X |
Currently Active Assets on Macroaxis
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.